Income Statement Aier Eye Hospital Group Co., Ltd.
Equities
300015
CNE100000GR6
Healthcare Facilities & Services
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.680 CNY | +3.64% | +2.22% | -38.81% |
26/08 | Citi Downgrades Aier Eye Hospital Group to Sell From Neutral; Price Target is 7 Yuan | MT |
26/08 | Aier Eye Hospital Group H1 Profit Up 20%, Operating Income Rises 3% | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 9.97B | 11.9B | 14.97B | 16.07B | 20.31B | |||||
Other Revenues, Total | 16.17M | 12.34M | 27.91M | 41.12M | 54.3M | |||||
Total Revenues | 9.99B | 11.91B | 15B | 16.11B | 20.37B | |||||
Cost of Goods Sold, Total | 5.06B | 5.84B | 7.21B | 7.98B | 10.02B | |||||
Gross Profit | 4.93B | 6.08B | 7.79B | 8.13B | 10.35B | |||||
Selling General & Admin Expenses, Total | 2.35B | 2.49B | 3.41B | 3.85B | 4.64B | |||||
Provision for Bad Debts | 68.38M | 90.53M | 97.89M | 77.27M | 107M | |||||
R&D Expenses | 151M | 163M | 221M | 270M | 331M | |||||
Other Operating Expenses | 22.19M | 30.41M | 41.32M | 44.62M | 45.65M | |||||
Other Operating Expenses, Total | 2.6B | 2.78B | 3.77B | 4.24B | 5.12B | |||||
Operating Income | 2.33B | 3.3B | 4.02B | 3.89B | 5.22B | |||||
Interest Expense, Total | -68.86M | -75.38M | -165M | -178M | -195M | |||||
Interest And Investment Income | 122M | 198M | 200M | 132M | 166M | |||||
Net Interest Expenses | 53.03M | 123M | 34.86M | -46.09M | -29.09M | |||||
Currency Exchange Gains (Loss) | 9.61M | -21.32M | 42.88M | 129M | 52.41M | |||||
Other Non Operating Income (Expenses) | -22.19M | -35.99M | -44.93M | -38.19M | -54.19M | |||||
EBT, Excl. Unusual Items | 2.37B | 3.37B | 4.05B | 3.93B | 5.19B | |||||
Impairment of Goodwill | -314M | -362M | -217M | -95.34M | -384M | |||||
Gain (Loss) On Sale Of Investments | -56.41M | -380M | -448M | -357M | -79.42M | |||||
Gain (Loss) On Sale Of Assets | -4.93M | 969K | 52.45K | -1.25M | 711K | |||||
Asset Writedown | - | -4.44M | -4.27M | -5.01M | -6.11M | |||||
Other Unusual Items | -154M | -257M | -238M | -138M | -173M | |||||
EBT, Incl. Unusual Items | 1.84B | 2.36B | 3.15B | 3.34B | 4.55B | |||||
Income Tax Expense | 409M | 486M | 678M | 646M | 895M | |||||
Earnings From Continuing Operations | 1.43B | 1.88B | 2.47B | 2.69B | 3.66B | |||||
Net Income to Company | 1.43B | 1.88B | 2.47B | 2.69B | 3.66B | |||||
Minority Interest | -52.24M | -153M | -147M | -165M | -297M | |||||
Net Income - (IS) | 1.38B | 1.72B | 2.32B | 2.52B | 3.36B | |||||
Net Income to Common Incl Extra Items | 1.38B | 1.72B | 2.32B | 2.52B | 3.36B | |||||
Net Income to Common Excl. Extra Items | 1.38B | 1.72B | 2.32B | 2.52B | 3.36B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.16 | 0.19 | 0.26 | 0.28 | 0.36 | |||||
Basic EPS - Continuing Operations | 0.16 | 0.19 | 0.26 | 0.28 | 0.36 | |||||
Basic Weighted Average Shares Outstanding | 8.78B | 8.92B | 9.05B | 8.99B | 9.22B | |||||
Net EPS - Diluted | 0.16 | 0.19 | 0.26 | 0.28 | 0.36 | |||||
Diluted EPS - Continuing Operations | 0.16 | 0.19 | 0.26 | 0.28 | 0.36 | |||||
Diluted Weighted Average Shares Outstanding | 8.79B | 8.92B | 9.05B | 8.99B | 9.25B | |||||
Normalized Basic EPS | 0.16 | 0.22 | 0.26 | 0.25 | 0.32 | |||||
Normalized Diluted EPS | 0.16 | 0.22 | 0.26 | 0.25 | 0.32 | |||||
Dividend Per Share | 0.05 | 0.07 | 0.07 | 0.08 | 0.15 | |||||
Payout Ratio | 37.28 | 30.79 | 28.51 | 26.64 | 22.24 | |||||
Supplemental Items | ||||||||||
EBITDA | 2.67B | 3.7B | 4.5B | 4.49B | 5.89B | |||||
EBITA | 2.33B | 3.3B | 4.03B | 3.91B | 5.23B | |||||
EBIT | 2.33B | 3.3B | 4.02B | 3.89B | 5.22B | |||||
EBITDAR | 2.73B | 3.78B | 4.51B | 4.51B | 5.9B | |||||
Total Revenues (As Reported) | 9.99B | 11.91B | 15B | 16.11B | 20.37B | |||||
Effective Tax Rate - (Ratio) | 22.23 | 20.57 | 21.53 | 19.37 | 19.67 | |||||
Current Domestic Taxes | - | - | - | - | - | |||||
Total Current Taxes | 411M | 520M | 712M | 666M | 868M | |||||
Deferred Domestic Taxes | - | - | - | - | - | |||||
Total Deferred Taxes | -2.23M | -34.22M | -33.76M | -19.53M | 26.6M | |||||
Normalized Net Income | 1.43B | 1.95B | 2.39B | 2.29B | 2.95B | |||||
Interest on Long-Term Debt | - | - | 139M | 156M | 16.95M | |||||
Non-Cash Pension Expense | - | - | - | 1.68M | 5.87M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | - | - | - | - | 937M | |||||
Marketing Expenses | 513M | 494M | 695M | 724M | - | |||||
Selling and Marketing Expenses | 1.05B | 1.07B | 1.45B | 1.56B | 1.97B | |||||
General and Administrative Expenses | 1.26B | 1.35B | 1.96B | 2.29B | 2.67B | |||||
Research And Development Expense From Footnotes | 152M | 164M | 223M | 272M | 333M | |||||
Net Rental Expense, Total | 58.13M | 80.83M | 13.22M | 22.26M | 11.99M | |||||
Imputed Operating Lease Interest Expense | 15.1M | 21.17M | 4.74M | 6.31M | 3.68M | |||||
Imputed Operating Lease Depreciation | 43.03M | 59.66M | 8.48M | 15.95M | 8.31M | |||||
Stock-Based Comp., G&A Exp. (Total) | 2.93M | 754K | 127M | 228M | 145M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 2.93M | 754K | 127M | 228M | 145M |